Syngene International, a global Contract Research Organization in association with industry leaders, Thermo Fisher Scientific and Amgen Inc., hosted a two -day scientific symposium titled ‘Next Generation Antibody Platforms’ on December 3-4th in Bengaluru. The symposium was hosted under the aegis of “INNO”, a platform that aims to facilitate knowledge-sharing among scientists across industry and academia.
The 2-day symposium was inaugurated by Kiran Mazumdar Shaw, MD, Syngene International Ltd., Jonathan Hunt, CEO, Syngene International Ltd., Philip Tagari, VP – Research, Amgen Inc. and Dara Wright, VP – Protein & Cell Analysis Unit. Speaking about the Symposium, Dr. Jayashree Aiyar, Chair of the Symposium and Vice President – Discovery Biology, Syngene International Ltd., said, “INNO is a great platform for budding scientists in the Pharma and Biotech space to widen their scientific horizon through interacting with global scientific thought leaders. It also provides them an opportunity to showcase their research work. This symposium on antibody research helped promote innovation, facilitate knowledge sharing on cutting-edge technologies and provided an excellent opportunity for budding scientists to interact with distinguished international speakers.”
The symposium boasted of a list of eminent speakers drawn from the academia and industry. The keynote addresses were delivered by Prof. Sachdev Sidhu from University of Toronto and Dr. Philip Tagari. Some of the eminent speakers included Andreas Menrad from Merck KGaA, Irina Rybina from Boehringer Ingelheim, Dinakar Salunke, Director International Centre for Genetic, Engineering and Biotechnology, Deepa Shankar from Thermo Fisher Scientific amongst others.
Biotherapeutics, particularly antibodies, have become a significant part of Pharma R&D efforts. According to a report by Grand View Research, the global antibody production market is expected to reach a value of USD 22.6 billion by 2025. Increasing demand for therapeutic antibodies is a major factor that drives growth of the market. This has led to many pharmaceuticals and biotechnology companies focusing on the development of advanced antibodies for the treatment of chronic diseases such as cancer, rheumatic heart disease, and arthritis.
More than 500 delegates from the industry and academia attended the symposium. Teams of scientists also presented scientific posters showcasing their cutting-edge research in the areas of antibody research.